# Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma

> **NCT07658924** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Cutaneous T-Cell Lymphoma
- Mycosis Fungoides (MF)

## Interventions

- **DRUG:** Benvitimod Cream
- **DRUG:** Placebo cream

## Key facts

- **NCT ID:** NCT07658924
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07658924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07658924, "Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07658924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*